Submitted:
14 July 2026
Posted:
16 July 2026
You are already at the latest version
Abstract
Keywords:
Introduction
Methods
Results
Discussion
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Mehta, Vikita; Kirubarajan, Abirami; Sabouhanian, Amir; Jayawardena, Sanasi M; Chandrakumaran, Priya; Thangavelu, Nila; Cader, Refai; et al. Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia. Acta Haematologica 2022, 145(3), 334–43. [Google Scholar] [CrossRef] [PubMed]
- Musallam, Khaled; Cappellini, Maria D; Taher, Ali. Challenges Associated with Prolonged Survival of Patients with Thalassemia: Transitioning from Childhood to Adulthood. Pediatrics 2008, 121(5), e1426-9. [Google Scholar] [CrossRef] [PubMed]
- Premawardhena, A; Fisher, C A; Olivieri, N F; de Silva, S; Arambepola, M; Perera, W; O’Donnell, A; et al. Haemoglobin E β Thalassaemia in Sri Lanka. The Lancet 2005, 366(9495), 1467–70. [Google Scholar] [CrossRef] [PubMed]
- Sleiman, Joseph; Tarhini, Ali; Bou-Fakhredin, Rayan; Saliba, Antoine N; Cappellini, Maria Domenica; Taher, Ali T. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. International Journal of Molecular Sciences 2018, 19(1). [Google Scholar] [CrossRef] [PubMed]
- Tahar, AT; Musallam, KM; Cappellini, MD. Leg Ulcers. In Guidelines for the Management of Non-Transfusion-Dependent β-Thalassaemia, 3rd Edition ed; Nicosia, 2023. [Google Scholar]
- Taher, A T; Musallam, K M; Karimi, M; El-Beshlawy, A; Belhoul, K; Daar, S; Saned, M; Cesaretti, C; Cappellini, M D. Splenectomy and Thrombosis: The Case of Thalassemia Intermedia. Journal of Thrombosis and Haemostasis 2010, 8(10), 2152–58. [Google Scholar] [CrossRef] [PubMed]
- Taher, Ali T; Musallam, Khaled M; El-Beshlawy, Amal; Karimi, Mehran; Daar, Shahina; Belhoul, Khawla; Saned, Mohamed-SalahEldin; Graziadei, Giovanna; Cappellini, Maria D. Age-Related Complications in Treatment-Naïve Patients with Thalassaemia Intermedia. British Journal of Haematology 2010, 150(4), 486–89. [Google Scholar] [CrossRef] [PubMed]

| Characteristic |
Control N = 421 |
Patient N = 421 |
p-value2 |
| Age at presentation (years) | 3.5 (0.8 - 9.0) | 1.8 (0.6 - 13.0) | 0.519 |
| Age at enrollment (years) | 31.8 (24.9 - 40.3) | 32.4 (27.8 - 43.8) | 0.720 |
| Sex | 0.999 | ||
| Female | 19 (45%) | 19 (45%) | |
| Male | 23 (55%) | 23 (55%) | |
| Genotype | 0.999 | ||
| HbE/β-thalassaemia | 15 (36%) | 15 (36%) | |
| Thalassaemia intermedia | 12 (29%) | 12 (29%) | |
| Thalassaemia major | 15 (36%) | 15 (36%) | |
| Follow-up time (years) | 11.0 (8.4 - 15.4) | 13.2 (11.2 - 15.8) | 0.137 |
| Number of visits | 69.5 (23.0 - 131.0) | 76.0 (33.0 - 146.0) | 0.434 |
| Units transfused | 137.5 (43.0 - 280.0) | 165.5 (73.0 - 323.0) | 0.348 |
| Minimum Hb | 5.6 (4.9 - 6.5) | 5.1 (4.2 - 5.8) | 0.027 |
| Mean Hb | 7.7 (6.9 - 8.5) | 7.2 (6.6 - 8.0) | 0.139 |
| Maximum Hb | 10.0 (8.5 - 10.6) | 9.9 (8.4 - 10.7) | 0.819 |
| Mean Hbf | 25.4 (11.3 - 50.7) | 14.1 (6.4 - 59.7) | 0.445 |
| Mean platelet | 299.0 (224.0 - 568.5) | 342.3 (236.0 - 517.3) | 0.857 |
| Mean ferritin | 1,389.7 (822.5 - 2,098.9) | 1,655.6 (860.9 - 2,349.5) | 0.316 |
| Mean t2 heart | 30.4 (23.3 - 37.2) | 37.2 (26.7 - 45.3) | 0.059 |
| Mean t2 liver | 6.3 (4.6 - 8.6) | 7.1 (5.6 - 8.3) | 0.655 |
| Splenectomy | 13 (31%) | 21 (50%) | 0.075 |
| Gall stones | 22 (52%) | 25 (60%) | 0.510 |
| Cholecystectomy | 9 (21%) | 11 (26%) | 0.608 |
| Diabetes | 8 (19%) | 7 (17%) | 0.776 |
| Bone pain | 2 (4.8%) | 6 (14%) | 0.265 |
| Fractures | 1 (2.4%) | 2 (4.8%) | 0.999 |
| Amputation | 0 (0%) | 2 (4.8%) | 0.494 |
| Cirrhosis | 2 (4.8%) | 5 (12%) | 0.433 |
| Hydroxyurea | 11 (26%) | 14 (33%) | 0.474 |
|
1 Median (Q1 - Q3); n (%); 2 Wilcoxon rank sum test; Pearson's Chi-squared test; Wilcoxon rank sum exact test; Fisher's exact test | |||
| For cases and controls | For cases | ||||
| Hb Threshold (<g/dL) | Cumulative Events (n) | Unadjusted Odds Ratio (95%CI) | P value | Unadjusted Odds Ratio (95%CI) | P value |
| 2.5 | 2 | 44.39 (1.51 - 1302.54) | 0.028 | 20.23 (1.07 - 384.19) | 0.045 |
| 3.0 | 3 | 16.73 (0.92 - 305.83) | 0.057 | 8.98 (0.75 - 107.7) | 0.083 |
| 3.5 | 3 | 6.03 (0.59 - 61.98) | 0.131 | 4.86 (0.55 - 42.61) | 0.153 |
| 4.0 | 3 | 3.68 (0.42 - 31.99) | 0.238 | 2.93 (0.40 - 21.70) | 0.292 |
| 4.5 | 6 | 3.68 (1.08 - 12.52) | 0.037 | 3.03 (0.95 - 9.61) | 0.060 |
| 5.0 | 12 | 3.81 (1.76 - 8.26) | 0.001 | 3.24 (1.55 - 6.80) | 0.002 |
| 5.5 | 12 | 1.93 (1.07 - 3.47) | 0.028 | 1.78 (1.01 - 3.15) | 0.046 |
| 6.0 | 16 | 1.03 (0.62 - 1.71) | 0.903 | 0.99 (0.61 - 1.61) | 0.969 |
| 6.5 | 22 | 0.90 (0.57 - 1.42) | 0.645 | 0.87 (0.57 - 1.35) | 0.546 |
| 7.0 | 26 | 0.72 (0.46 - 1.12) | 0.148 | 0.72 (0.47 - 1.11) | 0.138 |
| 7.5 | 31 | 0.83 (0.52 - 1.32) | 0.429 | 0.84 (0.54 - 1.31) | 0.444 |
| 8.0 | 38 | 0.86 (0.54 - 1.37) | 0.531 | 0.87 (0.56 - 1.36) | 0.545 |
| 8.5 | 42 | 1.18 (0.69 - 2.01) | 0.552 | 1.17 (0.70 - 1.95) | 0.559 |
| 9.0 | 43 | 0.69 (0.37 - 1.28) | 0.240 | 0.70 (0.38 - 1.27) | 0.238 |
| 9.5 | 43 | 0.65 (0.31 - 1.36) | 0.251 | 0.66 (0.32 - 1.36) | 0.261 |
| 10.0 | 43 | 1.29 (0.32 - 5.17) | 0.717 | 1.33 (0.34 - 5.11) | 0.681 |
| 10.5 | 43 | 1.42 (0.14 - 14.20) | 0.764 | 1.40 (0.15 -13.34) | 0.773 |
| 11.0 | 43 | 0.54 (0.03 - 9.08) | 0.669 | 0.47 (0.03 - 8.87) | 0.617 |
| 11.5 | 43 | 0.39 (0.02 - 9.42) | 0.563 | 0.40 (0.02 - 9.28) | 0.571 |
| Risk Factor | Partially adjusted OR (95% CI)* | P-value | Fully Adjusted OR (aOR, 95% CI)** | P-value |
| Severe Anaemia (Hb < 5.0 g/dL) | 2.87 (1.15–7.14) | 0.024 | 2.67 (1.08–6.62) | 0.034 |
| Follow-up Duration (per year) | 1.18 (1.11–1.25) | < 0.001 | 1.17 (1.11–1.25) | < 0.001 |
| Transfusion Burden (per unit) | 1.43 (1.12–1.82) | 0.004 | 1.43 (1.13–1.82) | 0.004 |
| Gender (Ref: Female): Male | 1.81 (0.16–21.05) | 0.635 | ||
| Genotype (Ref: HbE/β-thalassaemia) | ||||
| Thalassaemia Intermedia (TI) | 0.14 (0.01–3.21) | 0.221 | ||
| Thalassaemia Major (TM) | 0.13 (0.01–2.14) | 0.153 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).